WDFY1 and schizophrenia: Although our pharmacological treatments with LPS and Poly I:C do not induce changes on WDFY1 levels, we hypothesize that the sustained increase of WDFY1 levels in He–/– mice and schizophrenia patients could be due to an impairment of a proper neuroimmunomodulation that may have its origin in the early phases of the neurodevelopment, when Helios is specifically expressed (Martín-Ibáñez et al., 2012, 2017).